@article{ATM22117,
author = {Angelo Maria Patti and Rosaria Vincenza Giglio and Kalliopi Pafili and Manfredi Rizzo and Nikolaos Papanas},
title = {Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {Risk factors of gestational diabetes mellitus (GDM) include overweight, hormonal changes, previous GDM, a family history of type 2 diabetes mellitus (T2DM), and polycystic ovarian syndrome (1,2). In approximately 90% of women, metabolic perturbations are transient (1,2). However, some women progress to T2DM post-partum, with ongoing endothelial inflammation, early atherosclerosis, increased coagulation, insulin resistance, central adiposity, metabolic syndrome (MetS), atherogenic dyslipidaemia and cardiovascular (CV) complications (3-7).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/22117}
}